31 completed, 7 unknown, 1 terminated, 1 withdrawn. 19 Phase 4, 9 Phase 3, 7 Phase 2, 4 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Completed 15, Unknown 3, Withdrawn 1 |
| Phase 3 | 9 | Completed 8, Unknown 1 |
| Phase 2 | 7 | Completed 6, Terminated 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow PCV13: new trials by email Literature Review of PCV13 trials Research Report on PCV13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Clinical Trial of a Candidate PCV13 in Healthy People 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infections | Phase 1 | Unknown | Wuhan BravoVax Co., Ltd. | 264 | 2022-11-01 | 2022-11-17 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants AFX3772, Prevnar 13, Prevnar 20 - Pneumonia, Bacterial, Pneumococcal Infections | Phase 2 | Completed | GlaxoSmithKline | 388 | 2022-06-16 | 2026-10-09 |
| PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2) PPV23, PCV13, Saline for injection - Streptococcus Pneumonia | Phase 4 | Unknown | Liverpool School of Tropical Medicine | 516 | 2021-07-28 | 2023-01-05 |
| A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator ASP3772, PCV13 - Healthy Volunteers, Pneumococcal Disease | Phase 1 | Completed | Affinivax, Inc. | 75 | 2020-09-22 | 2022-06-06 |
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) V114, PCV13 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 694 | 2020-07-01 | 2023-07-28 |
| Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children PCV10, PCV13 - Pneumonia, Meningitis | Completed | University of Witwatersrand, South Africa | 600 | 2020-02-14 | 2024-08-23 | |
| Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine - Plasma Cell Neoplasm | Phase 4 | Completed | Emory University | 165 | 2019-10-18 | 2025-02-28 |
| A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years PCV13 - Pneumonia | Phase 4 | Completed | Beijing Minhai Biotechnology Co., Ltd | 621 | 2019-09-26 | 2024-01-18 |
| Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) V114, Prevnar 13® - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 606 | 2019-06-25 | 2023-01-13 |
| The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants PCV10, PCV13 - Pneumococcal Infection, Streptococcus Pneumoniae Infection | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 2100 | 2019-03-21 | 2024-11-12 |
| A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine ASP3772, PCV13, PPSV23 - Pneumonia, Bacterial, Healthy Volunteers | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 630 | 2019-01-24 | 2023-12-21 |
| Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia PCV13, PPSV23 - CLL, Vaccine Response | Phase 4 | Completed | Region Örebro County | 77 | 2019-01-01 | 2023-03-30 |
| CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study PCV13 - Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection | Phase 2 / Phase 3 | Completed | University of British Columbia | 248 | 2018-08-23 | 2024-03-04 |
| Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines PCV13, DTaP, HBV - Apnea, Apnea Neonatal | Phase 4 | Completed | Duke University | 223 | 2018-07-17 | 2024-02-14 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1515 | 2018-07-16 | 2021-01-15 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 652 | 2018-06-22 | 2021-11-02 |
| Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older HZ/su vaccine GSK1437173A, Prevenar13 - Herpes Zoster | Phase 3 | Completed | GlaxoSmithKline | 913 | 2018-04-12 | 2022-01-11 |
| Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy PCV13, PPV23, Rituximab - Invasive Pneumococcal Infection | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 96 | 2018-02-05 | 2025-11-20 |
| Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels PCV13, PPV23 - Pneumococcal Infections | Phase 4 | Completed | Jena University Hospital | 123 | 2017-10-18 | 2023-12-01 |
| Pneumococcal Vaccines in Patients With Asthma PCV13, PPSV23 - Asthma | Phase 4 | Completed | Mayo Clinic | 17 | 2017-10-01 | 2021-11-05 |
Showing 20 of 40. Sign in to see all of them.
Pneumococcal Infections (15) · Pneumonia (8) · Neoplasms, Plasma Cell (3) · Asthma (2) · Meningitis (2) · Multiple Myeloma (2) · Otitis Media (2) · Pneumonia, Bacterial (2) · Pneumonia, Pneumococcal (2) · Pulmonary Disease, Chronic Obstructive (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Apnea (1) · Arthritis, Rheumatoid (1) · Cough (1) · Fever (1)
Merck Sharp & Dohme LLC (4) · GlaxoSmithKline (3) · Aghia Sophia Children's Hospital of Athens (2) · Duke University (2) · London School of Hygiene and Tropical Medicine (2) · Menzies School of Health Research (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Affinivax, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Minhai Biotechnology Co., Ltd (1) · Canadian Immunization Research Network (1) · Chung-Ang University Hospital (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jena University Hospital (1)
United States (13) · Canada (4) · Russia (4) · Australia (3) · South Korea (3) · United Kingdom (3) · China (2) · Germany (2) · Poland (2) · Thailand (2) · Chile (1) · Estonia (1) · Finland (1) · France (1) · Greece (1)
Amanda J Leach, PhD (2) · Karen Broder, MD (2) · Aleksander V Zhestkov, Professor (1) · Andrea Trembath, MD (1) · Andrei D Protasov, Professor (1) · Andrew Pollard, FRCPCH, PhD (1) · Avni Y Joshi (1) · Bart JM Vlaminckx, Phd (1) · Bertil Uggla, Md, PhD (1) · Craig Hofmeister, MD, MPH (1) · Dror Harats, Prof. (1) · Ed Clarke, MB (1) · Edward K Mulholland, MBBS, FRACP (1)
PMID 35772449, PMID 38829821, PMID 24618837, PMID 24879786, PMID 25596202, PMID 25995224, PMID 27239929, PMID 28392142, PMID 28802755, PMID 29488477, PMID 29722823, PMID 29884695, PMID 30683996, PMID 30975525, PMID 32029684, PMID 32067048, PMID 32087733, PMID 32448790, PMID 33292822, PMID 33685411, PMID 33745731, PMID 33814028, PMID 34171233, PMID 34489128, PMID 34963639, PMID 35146039, PMID 35690500, PMID 35798520, PMID 36150974, PMID 36785850, PMID 37344262, PMID 37735756, PMID 38360475, PMID 39217777, PMID 39330966, PMID 39417218, PMID 39761016, PMID 40045895, PMID 40537903, PMID 41442837, PMID 41698388, PMID 42710524, PMID 42743942
2017 (3), 2019 (2), 2016 (1), 2018 (1), 2023 (1), P01CA015396 (1), P30CA006973 (1), P30CA138292 (1)